DR
DRTS.US Alpha Tau Medical Ltd
- Market cap
- USD 1.24B
- P/E
- -
- P/B
- 28.04x
- ROE
- -312.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is DRTS.US undervalued?
Graham numberThe Graham number of Alpha Tau Medical Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alpha Tau Medical Ltd fundamental analysis
No fundamental analysis for Alpha Tau Medical Ltd yet.
Alpha Tau Medical Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic colla…
Full company profileAlpha Tau Medical Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Alpha Tau Medical Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | -86.0K | -776K | -979K | -1.07M | -1.10M | -1.23M | - |
| Operating Income | -8.01M | -9.24M | -13.8M | -32.1M | -35.7M | -36.0M | -42.3M | -54.2M |
| EBITDA | -7.94M | -9.16M | -13.0M | -31.2M | -28.0M | -30.3M | -41.1M | -54.2M |
| Net Income | -8.46M | -8.88M | -27.3M | -33.8M | -29.2M | -31.8M | -42.6M | -138M |
| EPS | -0.13 | -0.13 | -0.40 | -0.53 | -0.42 | -0.45 | -0.53 | -1.51 |
| Balance Sheet | ||||||||
| Total Assets | 31.6M | 53.0M | 42.2M | 120M | 107M | 86.2M | 106M | 134M |
| Total Liabilities | 31.8M | 61.4M | 77.0M | 14.5M | 22.9M | 23.5M | 28.6M | 90.2M |
| Shareholders' Equity | -193K | -8.43M | -34.8M | 106M | 84.5M | 62.7M | 77.1M | 44.1M |
| Cash & Short-term Investments | 28.1M | 46.0M | 31.3M | 105M | 81.8M | 59.6M | 73.1M | 101M |
| Total Debt | - | 54.0M | 54.0M | 5.19M | 13.3M | 12.5M | 13.7M | 15.2M |
| Cash Flow | ||||||||
| Operating Cash Flow | -6.91M | -7.25M | -11.8M | -23.9M | -18.0M | -19.8M | -26.7M | - |
| Capital Expenditure | 1.29M | 3.77M | 2.93M | 904K | 6.40M | 2.24M | 6.08M | 0.00 |
| Free Cash Flow | -8.20M | -11.0M | -14.7M | -24.8M | -24.4M | -22.0M | -32.8M | - |
| Ratios | ||||||||
| ROE | - | - | - | -32.0% | -34.5% | -50.7% | -55.3% | -312.1% |
| ROA | -26.8% | -16.8% | -64.6% | -28.1% | -27.2% | -36.8% | -40.3% | -102.4% |
| Debt to Equity | - | - | - | 0.05x | 0.16x | 0.20x | 0.18x | 0.34x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Alpha Tau Medical Ltd dividends
Alpha Tau Medical Ltd has not paid dividends in the last 7 fiscal years.
Who owns Alpha Tau Medical Ltd
- Insiders 31.37%
- Institutions 11.38%
- Public & others 57.25%
- Shares outstanding 92.5M
- Free float 64.1M
Top funds holding DRTS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core MSCI EAFE ETF | 471K | 0.51% | 0.00% | Oct 2026 |
| SEB Nordamerikafond Småbolag | 266K | 0.29% | -3.26% | Sep 2026 |
| iShares MSCI EAFE Small-Cap ETF | 221K | 0.24% | 0.00% | Oct 2026 |
| ARK Israel Innovative Technology ETF | 155K | 0.17% | 0.00% | Oct 2026 |
| Adara Smaller Companies | 134K | 0.15% | -0.17% | Sep 2026 |
| iShares MSCI Israel ETF | 133K | 0.14% | 0.00% | Oct 2026 |
| Dunham Small Cap Growth N | 81.7K | 0.09% | +15.97% | Sep 2026 |
| iShares Core MSCI Total Intl Stk ETF | 62.4K | 0.07% | 0.00% | Oct 2026 |
| iShares MSCI World Small Cap ETF USD Acc | 55.4K | 0.06% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 53.4K | 0.06% | 0.00% | Aug 2026 |
| Vanguard Global Small-Cap Idx USD Acc | 46.3K | 0.05% | 0.00% | Sep 2026 |
| CREF Total Global Stock Account R3 | 39.2K | 0.04% | 0.00% | Aug 2026 |
| State Street® SPDR® S&P® Intl Sm Cp ETF | 38.0K | 0.04% | 0.00% | Oct 2026 |
| Fidelity Total International Index | 37.3K | 0.04% | 0.00% | Sep 2026 |
| UBS (CH) IF 2 EqsWrlexCHSmlIndNSL IB | 32.6K | 0.04% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite ETF | 31.7K | 0.03% | 0.00% | Oct 2026 |
| Even Herd Long Short ETF | 24.8K | 0.03% | 0.00% | Oct 2026 |
| L&G Global Small Cap Eq Idx C GBP Acc | 22.5K | 0.02% | 0.00% | Sep 2026 |
| Timber Point Global Allocations Instl | 20.0K | 0.02% | 0.00% | Jun 2026 |
| iShares Core MSCI Intl Dev Mkts ETF | 16.4K | 0.02% | 0.00% | Oct 2026 |
Top institutions holding DRTS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Gem Investment Advisors, LLC | 1.43M | 1.55% | +1,161.23% | Jun 2026 |
| HighTower Advisors, LLC | 875K | 0.95% | 0.00% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 773K | 0.84% | 0.00% | Jun 2026 |
| Aquamarine Financial (Cayman) Ltd | 722K | 0.78% | 0.00% | Jun 2026 |
| Pier Capital, LLC | 692K | 0.75% | 0.00% | Jun 2026 |
| UBS Group AG | 642K | 0.69% | +124.03% | Jun 2026 |
| Apella Capital, LLC | 382K | 0.41% | 0.00% | Jun 2026 |
| ARK Investment Management LLC | 277K | 0.30% | -5.15% | Jun 2026 |
| Polen Capital | 221K | 0.24% | 0.00% | Jun 2026 |
| The Colony Group LLC | 185K | 0.20% | +472.53% | Jun 2026 |
| Mariner Wealth Advisors LLC | 167K | 0.18% | +14.13% | Jun 2026 |
| Daytona Street Capital LLC | 146K | 0.16% | 0.00% | Jun 2026 |
| Kovitz Investment Group Partners, LLC | 135K | 0.15% | -8.24% | Jun 2026 |
| Easterly Investment Partners. | 129K | 0.14% | +20.83% | Jun 2026 |
| Wells Fargo & Co | 106K | 0.11% | +114.71% | Jun 2026 |
| Jane Street Group LLC | 91.1K | 0.10% | +20.66% | Jun 2026 |
| Citadel Advisors Llc | 61.6K | 0.07% | +73.92% | Jun 2026 |
| Dauntless Investment Group, LLC | 61.2K | 0.07% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 54.8K | 0.06% | +67.29% | Jun 2026 |
| Geode Capital Management, LLC | 53.4K | 0.06% | 0.00% | Jun 2026 |
Alpha Tau Medical Ltd company profile
- Company name
- Alpha Tau Medical Ltd
- Ticker
- DRTS.US
- ISIN
- IL0011839383
- Exchange
- USA Stocks
- Listed since
- Mar 8, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 121
- Fiscal year end
- December
- Address
- Kiryat HaMada St. 5, Jerusalem, Israel, 9777605
- Phone
- 972 3 577 4115
- Website
- alphatau.com
About Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
Alpha Tau Medical Ltd management
8- Mr. Uzi SoferCEO & Chairman · born 1970
- Mr. Raphi LevyChief Financial Officer · born 1985
- Mr. Amnon GatChief Operations Officer · born 1975
- Mr. Ronen SegalChief Technology Officer · born 1973
- Dr. Robert B. Den M.D.Chief Medical Officer & Member of Scientific Advisory Board · born 1979
- Prof. Yona KeisariChief Scientific Officer · born 1947
- Ms. Rebecca BeckerVice President of legal
- Ms. Yael ZeigerCorporate Controller · born 1983